In obese Wistar rats with T2DM, exogenous injection of adropin resulted in reduced blood glucose level, improved insulin sensitivity, ameliorated hyperlipidemia, and inhibited levels of inflammatory cytokines [37]. This evidence concerns the gene INS and hyperlipidemia.